Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Endocrinology · Autoimmune Polyendocrinopathy Syndrome Type 4

The Biology and Diagnosis of APS-4

At a Glance

APS-4 is diagnosed clinically when a person has two or more confirmed autoimmune diseases that do not match APS-1, APS-2, or APS-3. There is no single APS-4 gene or antibody panel; doctors use disease patterns, targeted autoantibodies, and individualized monitoring.

The biology of Autoimmune Polyendocrinopathy Syndrome Type 4 (APS-4) is best understood as a breakdown in the body’s sophisticated “educational system” for immune cells. While most people have an immune system that can distinguish between “self” (your own tissues) and “non-self” (viruses or bacteria), people with APS-4 experience a loss of immune tolerance [1][2]. This means the safeguards that normally prevent your immune system from attacking your own organs have failed, allowing “autoreactive” cells to cause damage [3][4].

Polygenic Susceptibility vs. Monogenic Syndromes

One of the most important biological distinctions between APS types is their genetic cause.

  • APS-1 is Monogenic: It is typically caused by a mutation in a single gene called AIRE (Autoimmune Regulator) [3][4]. This gene acts like a library in the thymus, showing developing immune cells a “catalog” of all the proteins in the body so they learn not to attack them. When AIRE is broken, the library is empty, and immune cells enter the body without knowing what to leave alone [3][1].
  • APS-4 Component Diseases Have Genetic Susceptibility: Unlike APS-1, APS-4 itself does not have a single genetic blueprint. Instead, many component autoimmune diseases have genetic susceptibility, often involving HLA (Human Leukocyte Antigen) genes and other immune-regulating genes [5][6]. HLA genes help the immune system recognize proteins. Routine polygenic testing does not establish or diagnose APS-4; it only shows a predisposition to certain component diseases [5][7].

Think of APS-1 like a single major bridge collapse due to one faulty bolt, while the component diseases of APS-4 are more like a traffic jam caused by several small road closures, bad weather, and a broken stoplight all happening at once.

The Role of Autoantibodies as “Biological Clues”

Doctors use autoantibodies—proteins produced by the immune system that mistakenly target the body’s own tissues—to understand which organs are under attack and to differentiate between the different types of APS. These markers are often present in the blood years before symptoms of a disease actually appear [8][9].

Common autoantibodies used in assessing component diseases of APS-4 include:

  • GAD65, IA-2, and ZnT8: These target the pancreas and are markers for Type 1 Diabetes risk [10][11].
  • 21-hydroxylase (21-OH): These target the adrenal glands. Their presence is a strong warning sign of evolving Addison disease [10][11].
  • TPO and Thyroglobulin: These target the thyroid gland [12].
  • Anti-Interferon Omega: These are “specialty” antibodies that can be highly specific for APECED/APS-1 when present. However, a negative result does not by itself exclude APS-1, particularly depending on age and disease manifestations. Diagnosis of APS-1 depends on the clinical pattern and, when indicated, AIRE genetic testing [13][14].

Note that these antibodies are markers for individual diseases, not a definitive APS-4 diagnostic panel.

Differentiating APS-4 from Other Types

APS-4 is a “diagnosis of exclusion,” meaning doctors arrive at it by systematically ruling out the patterns of the other three types. The exact combination of diseases you have is the primary way this is determined [15][16]:

If you have… And you also have… It is likely…
APS-1 Patterns Chronic yeast infections of skin/mucous membranes (candidiasis), low parathyroid hormone (hypoparathyroidism), AND primary adrenal insufficiency APS-1
Addison Disease Type 1 Diabetes OR Autoimmune Thyroid Disease APS-2
Autoimmune Thyroid Any other autoimmune disease except Addison APS-3
Any other combination Two or more confirmed autoimmune diseases that don’t fit the above APS-4

Because the manifestations of APS-4 can be separated by decades—sometimes appearing as much as 40 years apart—your “clinical picture” may change over time [9]. This is why individualized, risk-based monitoring of both your symptoms and your autoantibody levels is a standard part of long-term care [8].

Common questions in this guide

How is APS-4 diagnosed?
APS-4 is a clinical diagnosis, not a condition confirmed by one blood test or one gene. Doctors look for two or more confirmed autoimmune diseases and determine whether the combination does not fit the defining patterns of APS-1, APS-2, or APS-3.
Does a genetic test confirm APS-4?
No single genetic test confirms APS-4. HLA and other immune-related gene findings may show a tendency toward individual autoimmune diseases, but routine testing of many genes cannot establish APS-4; AIRE testing may be considered when the pattern raises concern for APS-1.
What do positive autoantibody results mean in APS-4?
Autoantibodies are immune proteins that mistakenly target the body's own tissues. Tests such as GAD65, IA-2, ZnT8, 21-hydroxylase, TPO, and thyroglobulin can point to risk involving specific organs, sometimes before symptoms appear, but no single antibody panel diagnoses APS-4.
How is APS-4 different from APS-1, APS-2, and APS-3?
APS-1 typically follows a single-gene AIRE change and has a characteristic combination that includes chronic candidiasis, hypoparathyroidism, and primary adrenal insufficiency. APS-2 includes Addison disease with type 1 diabetes or autoimmune thyroid disease, while APS-3 includes autoimmune thyroid disease with another autoimmune disease but not Addison disease. APS-4 describes two or more autoimmune diseases that do not fit those patterns.
Should I have anti-interferon omega or AIRE testing?
Anti-interferon omega antibodies can support an evaluation for APS-1 when the clinical pattern suggests it, but a negative result alone does not rule APS-1 out. When appropriate, doctors may use AIRE genetic testing together with age, symptoms, and the pattern of autoimmune diseases; these tests are not routine confirmation tests for APS-4.
Why might monitoring continue after APS-4 is diagnosed?
Autoimmune manifestations can appear many years apart, so the organs involved may change over time. Your clinician can tailor symptom review and repeat autoantibody testing to your history and risk profile; there is no single monitoring schedule for everyone.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Which specific autoantibodies were positive in my blood tests, and what organs do they correspond to?
  2. 2.Based on my clinical pattern, is there any reason to test for anti-interferon omega antibodies to support an evaluation for APS-1?
  3. 3.What HLA risk factors or other genetic markers were identified in my case, if any?
  4. 4.How does 'loss of tolerance' specifically manifest in my immune system—is it mainly targeting my glands, or other tissues too?
  5. 5.Since APS-4 is a clinical diagnosis, which specific combination of conditions in my history led to this classification?
  6. 6.How often should we repeat autoantibody testing to check for 'silent' autoimmune activity in new organs based on my risk profile?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (16)
  1. 1

    Characterisation of APS-1 Experimental Models Is Crucial for Development of Novel Therapies.

    Almaghrabi S, Lovewell T, Azzouz M, Tazi Ahnini R

    BioMed research international 2023; (2023()):7960443 doi:10.1155/2023/7960443.

    PMID: 36685668
  2. 2

    Where AIRE we now? Where AIRE we going?

    Bez P, Ceraudo M, Vianello F, et al.

    Current opinion in allergy and clinical immunology 2024; (24(6)):448-456 doi:10.1097/ACI.0000000000001041.

    PMID: 39440452
  3. 3

    Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy.

    Ferré EMN, Schmitt MM, Lionakis MS

    Frontiers in pediatrics 2021; (9()):723532 doi:10.3389/fped.2021.723532.

    PMID: 34790633
  4. 4

    AAV9-mediated AIRE gene delivery clears circulating antibodies and tissue T-cell infiltration in a mouse model of autoimmune polyglandular syndrome type-1.

    Almaghrabi S, Azzouz M, Tazi Ahnini R

    Clinical & translational immunology 2020; (9(9)):e1166 doi:10.1002/cti2.1166.

    PMID: 32994995
  5. 5

    The Putative Role of TIM-3 Variants in Polyendocrine Autoimmunity: Insights from a WES Investigation.

    Ariolli A, Agolini E, Mazza T, et al.

    International journal of molecular sciences 2024; (25(20)) doi:10.3390/ijms252010994.

    PMID: 39456777
  6. 6

    Novel Gene Mutations Regulating Immune Responses in Autoimmune Polyglandular Syndrome With an Atypical Course.

    Yukina M, Erofeeva T, Nuralieva N, et al.

    Journal of the Endocrine Society 2021; (5(8)):bvab077 doi:10.1210/jendso/bvab077.

    PMID: 34235359
  7. 7

    Analysis of the AIRE Gene Promoter in Patients Affected by Autoimmune Polyendocrine Syndromes.

    Cudini A, Nardella C, Bellacchio E, et al.

    International journal of molecular sciences 2024; (25(5)) doi:10.3390/ijms25052656.

    PMID: 38473903
  8. 8

    First proof of association between autoimmune polyglandular syndrome and multiple endocrine neoplasia in humans.

    Manso J, Censi S, Iacobone M, et al.

    Endocrine journal 2020; (67(9)):929-934 doi:10.1507/endocrj.EJ20-0099.

    PMID: 32475862
  9. 9

    Autoimmune polyglandular syndrome type 4: experience from a single reference center.

    Gatta E, Anelli V, Cimino E, et al.

    Frontiers in endocrinology 2023; (14()):1236878 doi:10.3389/fendo.2023.1236878.

    PMID: 37937054
  10. 10

    Multiplex Autoantibody Detection in Patients with Autoimmune Polyglandular Syndromes.

    Savvateeva EN, Yukina MY, Nuralieva NF, et al.

    International journal of molecular sciences 2021; (22(11)) doi:10.3390/ijms22115502.

    PMID: 34071130
  11. 11

    [The prevalence of newly diagnosed autoimmune diseases among patients with Graves' disease and autoimmune polyglandular syndrome of adults].

    Troshina EA, Larina AA, Sheremeta MS, Malisheva NM

    Terapevticheskii arkhiv 2020; (92(10)):9-14 doi:10.26442/00403660.2020.10.000737.

    PMID: 33346473
  12. 12

    Challenges in autoimmune polyendocrine syndrome type 2 with the full triad induced by anti-programmed cell death 1: a case report and review of the literature.

    Pan Q, Li P

    Frontiers in immunology 2024; (15()):1366335 doi:10.3389/fimmu.2024.1366335.

    PMID: 38707904
  13. 13

    Assessment of autoantibodies to interferon-ω in patients with autoimmune polyendocrine syndrome type 1: using a new immunoprecipitation assay.

    Larosa MDP, Mackenzie R, Burne P, et al.

    Clinical chemistry and laboratory medicine 2017; (55(7)):1003-1012.

    PMID: 28099118
  14. 14

    Autoantibodies against the calcium-sensing receptor and cytokines in autoimmune polyglandular syndromes types 2, 3 and 4.

    Kemp EH, Kahaly GJ, Porter JA, et al.

    Clinical endocrinology 2018; (88(1)):139-145 doi:10.1111/cen.13482.

    PMID: 28941288
  15. 15

    Case Report: Autoimmune polyglandular syndrome type 4 involving diabetes mellitus type 1, autoimmune hepatitis, immune thrombocytopenia, and celiac disease.

    Nesterowicz M, Anikiej K, Borysewicz-Sańczyk H, et al.

    Frontiers in endocrinology 2025; (16()):1655483 doi:10.3389/fendo.2025.1655483.

    PMID: 41169469
  16. 16

    Autoimmune polyglandular syndrome among Chinese celiac disease patients: a survey of 243 individuals in China.

    Xue S, Feng Y, Shi T, et al.

    Frontiers in immunology 2025; (16()):1606237 doi:10.3389/fimmu.2025.1606237.

    PMID: 40698092

This page explains APS-4 biology and diagnosis for informational purposes only and does not constitute medical advice. An endocrinologist or immunologist should interpret your autoimmune pattern and test results with you.

Get notified when new evidence is published on Autoimmune polyendocrinopathy type 4.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.